Professional association | Origin | Year | Condition | Threshold values for ID diagnostic | ||
---|---|---|---|---|---|---|
Serum ferritin (μg/L) | TSAT (%) | Additional biomarkers | ||||
General population | ||||||
 WHO [38] | International | 2020 | ID in |  | – | sTfR#, CRP** |
˗ Infants and children < 5 years |  < 12 | |||||
  with infection/inflammation |  < 30 | |||||
˗ Children > 5 years, adolescents, adults, older person (60 + years) |  < 15 | |||||
  with infection/inflammation |  < 70 | |||||
˗ Pregnant women (only for first trimester) |  < 15 | |||||
 AAFP [39] | American | 2013 | IDA |  < 30 | – | low serum iron#, low TSAT#, high TIBC# |
with infection/ inflammation |  < 50 | |||||
 BCG [40] | British | 2019 | ID in children |  < 12 | additional < 20 | serum iron#, TIBC#, TSAT |
- Possible ID | 12–20 | |||||
ID in adults |  < 15 | |||||
- Probable ID | 15–30 | |||||
- Unlikely ID |  > 30 | |||||
  or with chronic inflammatory disease |  > 70–100 | |||||
  or in elderly patients |  > 50 | |||||
Chronic heart failure (HF) | ||||||
 ACCF/AHA [30] | American | 2017 | AID |  < 100 | – | – |
FID | or 100–300 | and < 20 | ||||
 ESC [23] | European | 2021 | AID |  < 100 | and < 20 | sTfR# |
FID | or 100–299 | and < 20 | ||||
Chronic kidney disease (CKD) | ||||||
 KIDIGO [31] | International | 2012 | IDA only | – | – | – |
ND/HD-CKD + IDA |  ≤ 500 | and ≤ 30 | ||||
Pediatric CKD + IDA |  ≤ 100 | and ≤ 20 | ||||
Severe ID |  ≤ 30 | – | ||||
 KDOQI [32] | American | 2013 | IDA only | – | – | – |
 ERBP [33] | European | 2013 | ID/IDA (AID) |  < 100 | and < 20 | – |
 UK NICE [34] | British | 2021 | IDA only |  < 100* | and < 20* | Red blood cell markers: %HRC > 6%, CHr < 29 pg |
 JSDT [35] (2015 version) | Japanese | 2017 | HD-CKD + ID |  ≤ 100 |  ≤ 20 | – |
Inflammatory bowel disease (IBD) | ||||||
 ECCO [21] | European | 2015 | ID/IDA (quiescent disease, without inflammation) |  < 30 | – | Tests to distinguish between IDA and ACD: sTfR, sTfR–ferritin index |
AID and ACD | 30–100 | and/or < 20 | ||||
FID and ACD |  > 100 | and < 20 | ||||
 BSG [36] | British | 2021 | ID/IDA (AID) |  < 15 | – | sTfR# (in healthy subjects), sTfR–ferritin index#, CHr#, HYPO%# (in chronic disease and/or raised ESR#, CRP) |
FID |  ≥ 100 |  < 20 | ||||
Cancer | ||||||
 NCCN [37] | America | 2021 | ID/IDA (AID) |  < 30 | and < 20 | – |
FID (often when receiving ESAs) | 30–500 | and < 50 | ||||
Possible FID |  > 500–800 | and < 50 | ||||
 ESMO [20] | European | 2018 | ID/IDA (AID) |  < 30–100 | and < 20 | AID: sTfR#, ZPP# AID and FID: %HYPO > 5%, CHr < 28 pg, CRP** |
FID |  > 100 | and < 20 | ||||
 DGHO [11] | Germany | 2022 | ID/IDA (AID) |  < 30–100 |  < 20 | sTfR > 0.76–1.76 mg/L (Dade Behring Test), sTfR–ferritin index > 0.2–3.7 men, > 0.6–3.8 women (Roche Test), ZPP > 80 µmol/mol Häm, HYPO% > 10%, CHr < 26 pg, CRP** |
FID | 100–800 | and < 20 |